Medesis Pharma S.A. (ALMDP.PA)
EUR 0.34
(-2.86%)
EUR 0.34
(-2.86%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 300.03 Thousand EUR | 534.36% |
| 2022 | 47.29 Thousand EUR | -50.59% |
| 2021 | 95.72 Thousand EUR | -54.09% |
| 2020 | 208.5 Thousand EUR | -9.35% |
| 2019 | 230 Thousand EUR | 1990.91% |
| 2018 | 11 Thousand EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q4 | 16.24 Thousand EUR | 0.0% |
| 2023 Q2 | 133.77 Thousand EUR | 0.0% |
| 2023 Q1 | 133.77 Thousand EUR | 65.72% |
| 2023 Q3 | 16.24 Thousand EUR | -87.86% |
| 2023 FY | 300.03 Thousand EUR | 534.36% |
| 2022 Q1 | 17.92 Thousand EUR | 248.08% |
| 2022 Q4 | 80.72 Thousand EUR | 0.0% |
| 2022 Q3 | 80.72 Thousand EUR | 350.31% |
| 2022 Q2 | 17.92 Thousand EUR | 0.0% |
| 2022 FY | 47.29 Thousand EUR | -50.59% |
| 2021 FY | 95.72 Thousand EUR | -54.09% |
| 2021 Q4 | 5150.00 EUR | 0.0% |
| 2021 Q3 | 5150.00 EUR | -87.94% |
| 2021 Q2 | 42.71 Thousand EUR | 0.0% |
| 2021 Q1 | 42.71 Thousand EUR | -58.28% |
| 2020 FY | 208.5 Thousand EUR | -9.35% |
| 2020 Q4 | 102.38 Thousand EUR | 0.0% |
| 2020 Q3 | 102.38 Thousand EUR | 5395.76% |
| 2020 Q1 | 1864.00 EUR | 0.0% |
| 2020 Q2 | 1863.00 EUR | -0.05% |
| 2019 FY | 230 Thousand EUR | 1990.91% |
| 2018 FY | 11 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | 93.534% |
| ABIVAX Société Anonyme | 4.62 Million EUR | 93.507% |
| Adocia SA | 2.15 Million EUR | 86.045% |
| Aelis Farma SA | 9.05 Million EUR | 96.686% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | 90.478% |
| genOway Société anonyme | 20.04 Million EUR | 98.503% |
| IntegraGen SA | 12.53 Million EUR | 97.607% |
| Neovacs S.A. | 533.41 Thousand EUR | 43.752% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | 82.157% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -1415.629% |
| Sensorion SA | 4.74 Million EUR | 93.674% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -1.25% |
| TME Pharma N.V. | 17 Thousand EUR | -1664.906% |
| Valbiotis SA | 4.73 Million EUR | 93.661% |
| TheraVet SA | 1.07 Million EUR | 72.169% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | 83.331% |
| argenx SE | 1.13 Billion EUR | 99.974% |
| BioSenic S.A. | 543 Thousand EUR | 44.745% |
| Celyad Oncology SA | 102 Thousand EUR | -194.151% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 99.875% |
| Genfit S.A. | 28.56 Million EUR | 98.95% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | 85.624% |
| Innate Pharma S.A. | 51.9 Million EUR | 99.422% |
| Inventiva S.A. | 17.47 Million EUR | 98.283% |
| MaaT Pharma SA | 2.22 Million EUR | 86.533% |
| MedinCell S.A. | 9.16 Million EUR | 96.725% |
| Nanobiotix S.A. | 30.05 Million EUR | 99.002% |
| Onward Medical N.V. | 532 Thousand EUR | 43.603% |
| Oryzon Genomics S.A. | 14.19 Million EUR | 97.886% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 86.527% |
| Oxurion NV | 263 Thousand EUR | -14.081% |
| Pharming Group N.V. | 245.31 Million EUR | 99.878% |
| Poxel S.A. | 1.98 Million EUR | 84.854% |
| GenSight Biologics S.A. | 1.26 Million EUR | 76.319% |
| Transgene SA | 1.18 Million EUR | 74.659% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.994% |
| Valneva SE | 153.71 Million EUR | 99.805% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 108.288% |